ADAP Bullish Divergence, Low Risk PlayBullish divergence on the MACD and ADX. Price near last low. Low risk play with high potential in the short term. Longby DjentingaUpdated 0
$ADAP is gonna fall todayPupm&Dump trading strategy idea. $ADAP is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $6,29; stop-loss — $6,52; take-profit — $5,82/MOC Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!Shortby KozakHlib2
$ADAPDragon pattern. Weekly classic bullish divergence on the MACD. Stop = Close below resistance 1st Target = Resistance/0.236 fib extension 2nd Target = Resistance/0.5 fib extensionLongby Joshh_Tradess112
BUY ADAP - ADAPTIMMUNE THERAPEUTICS - STRONG BUY ON WEEKLY CHARTBUY ADAP - ADAPTIMMUNE THERAPEUTICS - STRONG BUY ON WEEKLY CHARTLongby easy_money_maker0
A Fantastic Bullish Setup on ADAPThis stock has shown breakout earlier creating wave 1 then it created its wave 3 when it had its stronger breakout now its doing a flat sideways tight range wave 4 The NEXT breakout will be a wave 5 up Longby iTradeAIMSUpdated 1110
SPEAR T-cell Platform Delivers Initial Responses in Four Solid TAdaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications -------------------------------------------------------------- Partial Responses seen in liver, melanoma, gastro-esophageal junction, and head and neck cancers. -------------------------------------------------------------- Encouraging demonstration of the potential of SPEAR T-cell platform across multiple targets and a range of solid tumors ---------------------------------------------------------- two confirmed Partial Responses (PRs) – one in a patient with liver cancer and one in a patient with melanoma. ---------------------------------------------------------- There are also two unconfirmed PRs – one in a patient with gastro‑esophageal junction cancer and one in a patient with head and neck cancer ---------------------------------------------------------- These data further confirm the potential of Adaptimmune’s SPEAR T-cell platform for patients with multiple solid tumors. ---------------------------------------------------------- These responses demonstrate that our proprietary SPEAR T-cell platform is clearly active and can overcome the challenges of treating a range of solid tumors with a T-cell therapy product- ---------------------------------------------------------- These are early results and we need more patient data and durability information to determine which therapies to develop. www.adaptimmune.comby AlenCiken3
SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in EGJIn the Surpass trial, three of the first four patients treated with ADP-A2M4CD8 had smaller tumors at the last checkup than they did at the outset. ---------------------------------------------------------- Eight out of 16 patients with synovial sarcoma have shown partial responses to treatment with ADP-A2M4. --------------------------------------------------------- Two out of three esophagogastric junction (EGJ) cancer patients treated with ADP-A2M4CD8 showed partial tumor shrinkage. --------------------------------------------------------- Also, one out of three liver cancer patients treated with ADP-A2AFP that had a partial response earlier this year has improved to a complete response. This sign of durability was particularly encouraging because this was the first patient treated with this candidate at the target dosage. --------------------------------------------------------- Adaptimmune doesn't have any approved products to sell yet, but new tumor responses reported today suggest the company's headed toward commercialization in more directions than previously expected. Adaptimmune intends to complete the recruitment of synovial sarcoma patients into the Spearhead-1 trial with ADP-A2M4 by the end of June, and based on today's update, the company thinks the trial will support an accelerated approval followed by a commercial launch in 2022. Based on responses from EGJ patients treated with ADP-A2M4CD8 so far, Adaptimmune will start a new phase 2 study focused on this indication. Despite today's big run-up, there could be a lot more room for this stock to climb if its cell-based cancer therapy candidates continue to impress. www.fool.com www.adaptimmune.comby AlenCiken2
ADAP SHORT TRADE IDEAThis over reaction to news and an approval may result in another handle on this left-facing cup and handle. Best of luck. -zmShortby Z3R0Matrix4
$ADAP can rise in the next daysContextual immersion trading strategy idea. Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. Friday morning the company presented positive data on its experimental cell therapy, which is designed to treat a range of cancers. It causes a rise in the share price. I see some preconditions the share price will continue growing. The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price in the next days. So I opened a long position from $11,85; stop-loss — $11,18. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!Longby KozakHlib4
ADAP went too far up too fastThere's absolutely no reason this security should have exploded higher like this. Would not be the least bit surprised to see a pullback to $7-8 after a big pump like this. One way you could play it is with low cost $5 strike puts.Shortby dotpem6
ADAP: daily log. Take a look.More speculative as is a bio pharmaceutical. One bad news release can lead to big drop. Chart looks good to me. Notice the positive reversal in the daily RSI. Could use close below the current up trend line as a stop.Yellow box is near term target but if price blasts though that level it would be very bullish. Process your way. Take care. Longby goodguyUpdated 4
ADAP Wedge BreakDouble Bottom at 3.60...long term support. Breaking through the wedge now. Clinical trial results in May.Longby dfwhockeyguy4
Long Position ADAP - Reaching All time low (BE CAUTIOUS)As the company ADAP has not been performing as desired within the last few years, an analysis may manifest that the trajectory for the stock valuation has almost amassed an all-time low valuation. Not investment advice. For personal and educational purposes only. (Move with caution and due diligence)Longby LionGateUpdated 1
Entry for long positionStrong Fundamental data has created the more recent bullish trend. I have been waiting for a safe entry point for about 2 months now after selling off some profits in the 13s. mid 10s has been my forecast for optimum entry for some time now and it looks like we are just about there. I am thinking that I will phase in throughout this week and set a stop around 9.75. Profit targets are hard to project but my gut tells me somewhere around mid 17s.Longby JasonSpence3
Long ADAPI am basing my speculations for this stock purely off my TA. ADAP is showing many indication that the stock is a good pick when Investing long (3 months to 1 year). However i don't think today is the best day to get on the train. I believe that ADAP is slightly overbought at the moment and in the short term, it will correct in price. There will be an opportunity to buy in the next few days. When ADAP was listed on the NASDAQ in late 2015 the stock price dropped to from 20$ to about 4$, loosing 4/5 of its value. From 2017 to the present, ADAP is growing at a steady pace and following a steady trend line up. The crash of ADAP from 2015-16 indicates that this stock has the potential to grow to its previous highs and maybe even then some. If you plan on making a long term position in ADAP, I think buying in the next couple days could put you in a good position. One pattern I recognized on the chart was an inverse triple bottom. Although this is usually a bearish indicator, because the neckline of the Triple bottom is not horizontal, I believe that this indicates a slight correction down to about 10-8$ a share and nothing more. There is too much built up support for ADAP to fall past 8$, and this is why I think 8-10$ is the ideal price to get in on. I hope found found my analysis helpful, please let me know what you think! Thanks, Colm :)Longby CryptoColm335
adap looking primed could be almost ready to go will wait for the breakout and buy above 8.22 target possible to $10Longby wolfstreetswingerUpdated 555
BUY $ADAP TARGET 1 Price: 10.32 Profit: 34.7% TARGET 1 Price: 10.32 Profit: 34.7% (Typical rally) Stop/Trailing Stop: 7.01 Loss: 8.5% P/L Ratio: 4.1 : 1 - ExcellentLongby swingstocktraders0